Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1601092

Cc1n[nH]c2ccc(-c3nnc(NCCCNCc4cc5ccccc5[nH]4)s3)cc12.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 7/20 0.40
CDK2 P24941 6/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
PIM1 P11309 5/20 0.38
PIM3 Q86V86 5/20 0.38
PIM2 Q9P1W9 4/20 0.38
DRD4 P21917 2/20 0.36
CLK2 P49760 1/20 0.34
CLK3 P49761 1/20 0.34
DYRK1A Q13627 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
ADRB2 P07550 1/20 0.34
CHRM2 P08172 1/20 0.34
ADRB1 P08588 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1601090 0.85 AKT1 (0.46) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1601858 0.77 AKT1 (0.55) AKT1CDK2PIM1PIM3
Trifluoroacetic Acid SCHEMBL1600849 0.77 AKT1 (0.40) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1601134 0.76 AKT1 (0.53) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1602115 0.75 AKT1 (0.52) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1602118 0.75 AKT1 (0.52) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1602039 0.74 GSK3B (0.43) CDK2DYRK1A
Hydrochloric Acid SCHEMBL1601116 0.74 PIM1 (0.48) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1600521 0.74 AKT1 (0.40) AKT1CDK2PIM1PIM3PIM2
Trifluoroacetic Acid SCHEMBL1600844 0.74 AKT1 (0.56) AKT1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809282-B1 THIADIAZOLE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2013-01-09 EP disclosed
US-7919514-B2 Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives AMGEN INC. (US) 2011-04-05 US disclosed
US-7700636-B2 Thiadiazole compounds and methods of use AMGEN INC. (US) 2010-04-20 US disclosed
US-20080269243-A1 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-10-30 US disclosed
US-20080255145-A1 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-10-16 US disclosed
US-7354944-B2 Thiadiazole compounds and methods of use AMGEN INC. (US) 2008-04-08 US disclosed
US-20060154961-A1 Thiadiazole compounds and methods of use AMGEN INC. 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255145-A1 Thiadiazole compounds and methods of use PDK2, PDK1, PANK2 AKT1 23/4885CDK2 124/4885HDAC3 480/4885
US-20080269243-A1 Thiadiazole compounds and methods of use PDK2, PDK1, PANK2 AKT1 23/4885CDK2 124/4885HDAC3 480/4885
US-20060154961-A1 Thiadiazole compounds and methods of use PDK2, PDK1, PANK2 AKT1 23/4885CDK2 124/4885HDAC3 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.